© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Nicholas Vogelzang, MD, FASCO, FACP, comments on managing an elderly patient with hormone-sensitive prostate cancer with apalutamide and ADT based on data demonstrated by the phase 3 TITAN trial.
February 9th 2021
An overview of the diagnostic work-up and treatment options offered to a 76-year-old male with castrate-sensitive prostate cancer who experiences recurrence.
Important considerations for oncologists who manage prostate cancer when establishing a treatment plan for a patient with castrate-sensitive disease.
Current treatment options available to treat hormone-sensitive prostate cancer in the first-line setting and factors that impact treatment selection.
The importance of risk stratifying patients with hormone-sensitive prostate cancer, and recommendations for germline and somatic testing.
Second-line therapies available to treat hormone-sensitive prostate cancer and recommendations for use based on current clinical data.
Best practices for monitoring patients’ response to AR-targeted therapy as used to treat castrate-sensitive prostate cancer and considerations for managing patients to help prevent the emergence of castrate-resistant disease.
An overview of the phase 3 TITAN trial in castrate-sensitive prostate cancer and implications for treating appropriate patients with apalutamide and androgen deprivation therapy.
Nicholas Vogelzang, MD, FASCO, FACP, reacts to treatment advances in hormone-sensitive prostate cancer and provides advice to oncologists who work in community settings on best practices for managing these patients using newer treatment strategies.